Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase

Sarah C. Zimmermann, Bridget Duvall, Takashi Tsukamoto

Research output: Contribution to journalArticlepeer-review

Abstract

Kidney-type glutaminase (GLS), the first enzyme in the glutaminolysis pathway, catalyzes the hydrolysis of glutamine to glutamate. GLS was found to be upregulated in many glutamine-dependent cancer cells. Therefore, selective inhibition of GLS has gained substantial interest as a therapeutic approach targeting cancer metabolism. Bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide (BPTES), despite its poor physicochemical properties, has served as a key molecular template in subsequent efforts to identify more potent and drug-like allosteric GLS inhibitors. This review article provides an overview of the progress made to date in the development of GLS inhibitors and highlights the remarkable transformation of the unfavorable lead into "druglike" compounds guided by systematic SAR studies.

Original languageEnglish (US)
Pages (from-to)46-59
Number of pages14
JournalJournal of medicinal chemistry
Volume62
Issue number1
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase'. Together they form a unique fingerprint.

Cite this